卡莫氟,Carmofur;≥98% (HPLC), powder

别名:5-氟-1-己基氨基甲酰基尿嘧啶;1-Hexylcarbamoyl-5-fluorouracil;HCFU;5-fluoro-N-hexyl-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-carboxamide;5-fluoro-N-hexyl-2,4-dioxopyrimidine-1-carb

Empirical Formula (Hill Notation): C11H16FN3O3 CAS号: 61422-45-5 分子量: 257.26 MDL编号: MFCD00866284 PubChem化学物质编号: 329774890 NACRES: NA.77
制造商品牌: 西格玛 Sigma-Aldrich
货号(SKU): C1494
CAS号: 61422-45-5
MDL号: MFCD00866284
签订合同 √ 正规发票 √ 技术支持 √ 质量保障 √ 全程可追溯 √
¥887.05

说明

强酸神经酰胺酶抑制剂(IC 50 = 29 nM)。抗代谢药。胞嘧啶嘧啶类似物衍生物的氟尿嘧啶(Asc 2387)。在体内显示抗肿瘤作用。Carmofur已被用作酸性神经酰胺酶抑制剂,以研究其对人胚肾 293T (HEK293T) 细胞中葡萄糖基鞘氨醇 (GlcSph) 生成的影响。它还被用作酸性神经酰胺酶的抑制剂,以研究其对酸介导的神经酰胺水解的影响,神经酰胺会启动消耗和鞘氨醇的产生。

应用

Carmofur has been used as an inhibitor of acid ceramidase to study its effects on glucosylsphingosine (GlcSph) production in human embryonic kidney 293T (HEK293T) cells.[1] It has also been used as an inhibitor of acid ceramidase to study its effects on acid‐mediated hydrolysis of ceramide which kicks-in consumption and the generation of sphingosine [2].
 

生化/生理作用

Carmofur acts as an inhibitor of fatty acid amide hydrolase (FAAH), N-acylethanolamine acid amidase (NAAA) and acid ceramidase (ASAH1).[3][4] Carmofur has a therapeutic activity against colorectal and cervical cancer.[5][4] It can inhibit the severe acute respiratory syndrome (SARS)-CoV-2 main protease (Mproin vitro.[5]
Carmofur is a derivative of fluorouracil, an antimetabolite used as an antineoplastic agent.
 
 

属性

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to off-white

溶解性

DMSO: >15 mg/mL

储存温度

2-8°C

SMILES string

CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O

InChI

1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)

InChI key

AOCCBINRVIKJHY-UHFFFAOYSA-N

 

安全信息

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 3 Oral - Repr. 2

储存分类代码

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

商品规格
属性名称属性值
储存温度 Storage temp.2-8°C冷藏
全球实时库存 Availability √美国St. Louis ≥ 20 | 欧洲Eur. ≥ 16 | 東京Tokyo ≥ 5 | 香港与北京 ≥ 20